- Central Florida Division External Communications

A new device that uses the power of the brain and nervous system to fight cardiovascular disease is giving new hope to the millions of Americans suffering from heart failure. Physicians at AdventHealth Orlando, who are among the earliest in the U.S. selected to use the Barostim Neo, say the pacemaker-like device is among the greatest advancements in treating heart failure, which costs the U.S. more than $30 million annually.
The Barostim Neo works to combat heart failure using neuromodulation — a growing trend in medical therapy that uses impulses from the brain to trigger physiological changes in the body. As the first neuromodulation device used to fight cardiovascular disease, the Barostim Neo stimulates a group of cells called baroreceptors to balance the body’s out-of-control fight or flight response when the heart is overstimulated.
A three-phase clinical trial concluded that patients implanted with the Barostim Neo had improved blood pressure, heart rate and quality of life. These patients were more likely to return to their normal lives — exercising, going to work and participating in hobbies as they once did before being diagnosed.
Dr. Nirav Raval, medical director of thoracic transplant at AdventHealth Transplant Institute, is the principal investigator for the study for AdventHealth. He was on the ground floor of the device’s development, first getting involved in early 2012.
“Investments in research and novel technologies are improving lives in ways we’ve never seen before,” Raval said. “With a growing number of Americans suffering with heart failure, it’s become increasingly important to develop less invasive, cost-effective devices to extend lives. The Barostim Neo is a step in that direction — improving heart failure to give patients the ability to enjoy better quality of life for a longer period of time.”
AdventHealth Orlando is the highest enrolling trial site in Florida, and the team has implanted four Barostim Neo devices to date. The hospital’s cardiovascular program treats more cardiovascular surgery patients than any other hospital in the state, according to the American Health Care Association.
“The Barostim Neo gave me my life back,” said Eric Berkowitz, a patient in the clinical trial at AdventHealth Orlando. “The device allows me to walk a two-mile track with my dog without panting and once again participate in the activities I’ve always enjoyed.”
Currently, the only way to receive the Barostim Neo is through an ongoing trial. For more information about the device, visit www.beathf.com.
Recent News
AdventHealth Centra Care Medical Director Tim Hendrix, MD, explains the symptoms of and the prevention strategies for the "quad-demic" of illnesses going around.
AdventHealth has named Khelsea Bauer president/CEO for AdventHealth DeLand, effective Feb. 23.
AdventHealth has reached a major milestone by welcoming its 100,000th team member to the health system’s skilled and compassionate workforce.
The 3D Motion Lab at AdventHealth Sports Med and Rehab Innovation Tower is the only of its kind in Florida.
AdventHealth Cancer Institute Winter Park's infusion center provides a warm and supportive environment, complete with recliners, TVs, nourishment stations and a private room.
AdventHealth Waterman's new boutique offers free wigs to women experiencing medical-related hair loss.
The degree is designed for nurses aspiring to advance their career.
The Freytag Cancer Center brings advanced medical treatments and compassionate care to one of the fastest-growing parts of Florida.
AdventHealth has named Eric Lunde president and chief executive officer for AdventHealth Fish Memorial, located in Orange City, Florida, effective Feb. 9, 2025.
Across AdventHealth, a community of team members unites under a shared mission, serving more than 8 million patients annually.
Darin Santangelo -- AdventHealth Orlando's executive director of procedural services -- said that he couldn't run to his mailbox when he began training for an Ironman Triathlon.
Health officials said Monday that a Louisiana patient who had been hospitalized with H5N1 died, marking the first U.S. death from bird flu.